Skip to main content

Table 3 Results of clinical trials by genotyping modality

From: Gel versus capillary electrophoresis genotyping for categorizing treatment outcomes in two anti-malarial trials in Uganda

Study Location Treatment Arm Genotyping-corrected 42-day Risk of Treatment Failure, % (95% CI) Risk Difference,
Gel vs. CE, % (p value)
   Gel CE  
Kanungu AL 6.9 (3.8-12.1) 5.5 (2.9-10.3) 1.4 (0.4)
  DP 2.4 (1.0-5.7) 2.9 (1.3-6.3) -0.5 (0.5)
Risk Difference,
AL vs. DP, % (p value)
4.5 (0.07) 2.6 (0.3)  
Apac AL 17.0 (11.8-24.0) 10.7 (6.6-17.1) 6.3 (0.02)
  DP 8.5 (5.2-13.7) 3.4 (1.5-7.4) 5.1 (0.03)
Risk Difference,
AL vs. DP, % (p value)
8.5 (0.03) 7.3 (0.02)  
  1. Risks of treatment failure calculated using the Kaplan-Meier product limit formula; p-values for risk differences calculated from 1,000 bootstrap repetitions.